Function Health raised $450 million in growth financing from General Catalyst’s Customer Value Fund, just eight months after its $298 million Series B. The lab-testing startup plans to use the capital to expand access to its testing and imaging services. The post Why General Catalyst Is Betting $450M on Function Health’s Preventive Care Push appeared…
A handful of former public health officials are campaigning for top statewide offices across the country, testing whether their experience with covid and other hot-button health issues will appeal to voters in November. The officials, all Democrats, are running at a time when the Trump administration is reducing government funding for scientific research, restricting access…
LUMBERTON, N.C. — Soybean fields surround Angie Lowery’s home in Robeson County, on a plot of rural land in southeastern North Carolina. Dozens of antique gas station signs, 20 feet tall, dominate her front yard. A framed re-creation of The Last Supper, Lone Ranger posters, and a 3-foot-wide tobacco harvesting basket adorn the walls of…
MedCity News’ new event for healthcare investors and corporate business development leads — Bullseye — hit the mark when it comes to provocative and thoughtful commentary. Here’s what was said in panels throughout the day. The post We Are Rats; If Pharma Could Be Brave … And Other Bullseye POVs You Won’t Hear at Other…
By JOHN SAMARAS Eli Lilly sells a month of 10mg Zepbound for $449 through LillyDirect, its own pharmacy. That price holds only if you refill within 45 days of your last fill. Refill on day 46 and the same box is $699. The $250 is a late fee. Here are the two ways to buy…
The FTC and the states of Utah and California sued Hims & Hers, alleging it improperly shared consumers’ health information and misled customers about billing, subscriptions and cancellations. The post Why Hims & Hers Is Embroiled in Yet Another Controversy, This Time with the FTC appeared first on MedCity News.
Company is expanding its proprietary technology, ScopeAI, across its 100 clinics, virtual care, and field medicine services in California, New York City, and Rhode Island
Johnson & Johnson also gains an exclusive option to acquire Sail Biosciences for $2.85 billion. The deal puts J&J in the mix of pharmaceutical companies developing next-generation cell therapies for applications in autoimmune diseases. The post J&J Joins Immune Reset Race, Paying $785M to Partner on Sail Bio Cell Therapy appeared first on MedCity News.
After Jaewon Ryu’s departure, Dale Maxwell, former president and CEO of Presbyterian Healthcare Services, will serve as interim CEO
This brief provides data on health and health care experiences of uninsured immigrant adults based on a KFF survey of immigrant adults ages 18 and older conducted in partnership with The New York Times in Fall 2025. The data provide insight into how the projected coverage losses under the 2025 reconciliation law may impact health…